Allergy Therapeutics (AGY) Competitors

Allergy Therapeutics logo
GBX 1.44 -0.06 (-3.69%)
As of 09:59 AM Eastern

AGY vs. BXP, ANCR, BVXP, VLG, and ORPH

Should you buy Allergy Therapeutics stock or one of its competitors? Allergy Therapeutics's main competitors and comparable companies include Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Bioventix (BVXP), Venture Life Group (VLG), and Open Orphan (ORPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Allergy Therapeutics compare to Beximco Pharmaceuticals?

Beximco Pharmaceuticals (LON:BXP) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Beximco Pharmaceuticals has a net margin of 16.04% compared to Allergy Therapeutics' net margin of -86.04%. Allergy Therapeutics' return on equity of 1,684.19% beat Beximco Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.04% 15.25% 6.97%
Allergy Therapeutics -86.04%1,684.19%-34.76%

Beximco Pharmaceuticals has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£56.27B0.00£970.84B£1.94 thousand0.03
Allergy Therapeutics£57.29M1.55-£52.59M-£0.97N/A

Beximco Pharmaceuticals has a beta of 0.248, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.835, suggesting that its share price is 17% less volatile than the broader market.

0.3% of Beximco Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are held by institutional investors. 4.2% of Beximco Pharmaceuticals shares are held by insiders. Comparatively, 3.6% of Allergy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Allergy Therapeutics had 2 more articles in the media than Beximco Pharmaceuticals. MarketBeat recorded 2 mentions for Allergy Therapeutics and 0 mentions for Beximco Pharmaceuticals. Beximco Pharmaceuticals' average media sentiment score of 0.00 beat Allergy Therapeutics' score of -0.19 indicating that Beximco Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Allergy Therapeutics Neutral

Summary

Beximco Pharmaceuticals beats Allergy Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Allergy Therapeutics compare to Animalcare Group?

Animalcare Group (LON:ANCR) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Animalcare Group has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.835, suggesting that its share price is 17% less volatile than the broader market.

In the previous week, Allergy Therapeutics had 2 more articles in the media than Animalcare Group. MarketBeat recorded 2 mentions for Allergy Therapeutics and 0 mentions for Animalcare Group. Animalcare Group's average media sentiment score of 0.00 beat Allergy Therapeutics' score of -0.19 indicating that Animalcare Group is being referred to more favorably in the media.

Company Overall Sentiment
Animalcare Group Neutral
Allergy Therapeutics Neutral

Animalcare Group has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Animalcare Group£89.11M2.60£36.55M£7.3045.89
Allergy Therapeutics£57.29M1.55-£52.59M-£0.97N/A

14.3% of Animalcare Group shares are owned by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are owned by institutional investors. 30.1% of Animalcare Group shares are owned by company insiders. Comparatively, 3.6% of Allergy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Animalcare Group has a net margin of 5.70% compared to Allergy Therapeutics' net margin of -86.04%. Allergy Therapeutics' return on equity of 1,684.19% beat Animalcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Animalcare Group5.70% 4.46% 2.97%
Allergy Therapeutics -86.04%1,684.19%-34.76%

Summary

Animalcare Group beats Allergy Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Allergy Therapeutics compare to Bioventix?

Bioventix (LON:BVXP) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

In the previous week, Allergy Therapeutics had 2 more articles in the media than Bioventix. MarketBeat recorded 2 mentions for Allergy Therapeutics and 0 mentions for Bioventix. Bioventix's average media sentiment score of 0.00 beat Allergy Therapeutics' score of -0.19 indicating that Bioventix is being referred to more favorably in the media.

Company Overall Sentiment
Bioventix Neutral
Allergy Therapeutics Neutral

20.6% of Bioventix shares are held by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are held by institutional investors. 6.2% of Bioventix shares are held by insiders. Comparatively, 3.6% of Allergy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bioventix has a beta of 0.541, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.835, indicating that its stock price is 17% less volatile than the broader market.

Bioventix has a net margin of 58.70% compared to Allergy Therapeutics' net margin of -86.04%. Allergy Therapeutics' return on equity of 1,684.19% beat Bioventix's return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix58.70% 67.81% 54.07%
Allergy Therapeutics -86.04%1,684.19%-34.76%

Bioventix has higher earnings, but lower revenue than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.97M7.65£8.12M£143.6213.23
Allergy Therapeutics£57.29M1.55-£52.59M-£0.97N/A

Summary

Bioventix beats Allergy Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Allergy Therapeutics compare to Venture Life Group?

Allergy Therapeutics (LON:AGY) and Venture Life Group (LON:VLG) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Venture Life Group has a net margin of 17.42% compared to Allergy Therapeutics' net margin of -86.04%. Allergy Therapeutics' return on equity of 1,684.19% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-86.04% 1,684.19% -34.76%
Venture Life Group 17.42%7.82%1.56%

Allergy Therapeutics has a beta of 0.835, meaning that its share price is 17% less volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.234, meaning that its share price is 77% less volatile than the broader market.

0.0% of Allergy Therapeutics shares are owned by institutional investors. Comparatively, 20.7% of Venture Life Group shares are owned by institutional investors. 3.6% of Allergy Therapeutics shares are owned by insiders. Comparatively, 7.7% of Venture Life Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Venture Life Group has lower revenue, but higher earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M1.55-£52.59M-£0.97N/A
Venture Life Group£35.17M2.34£747.21K£4.3715.83

In the previous week, Allergy Therapeutics had 2 more articles in the media than Venture Life Group. MarketBeat recorded 2 mentions for Allergy Therapeutics and 0 mentions for Venture Life Group. Venture Life Group's average media sentiment score of 0.00 beat Allergy Therapeutics' score of -0.19 indicating that Venture Life Group is being referred to more favorably in the news media.

Company Overall Sentiment
Allergy Therapeutics Neutral
Venture Life Group Neutral

Summary

Venture Life Group beats Allergy Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Allergy Therapeutics compare to Open Orphan?

Allergy Therapeutics (LON:AGY) and Open Orphan (LON:ORPH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Open Orphan has lower revenue, but higher earnings than Allergy Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M1.55-£52.59M-£0.97N/A
Open Orphan£34.71M0.00N/AN/AN/A

Open Orphan has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -86.04%. Allergy Therapeutics' return on equity of 1,684.19% beat Open Orphan's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-86.04% 1,684.19% -34.76%
Open Orphan N/A N/A N/A

0.0% of Allergy Therapeutics shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Allergy Therapeutics had 2 more articles in the media than Open Orphan. MarketBeat recorded 2 mentions for Allergy Therapeutics and 0 mentions for Open Orphan. Open Orphan's average media sentiment score of 0.00 beat Allergy Therapeutics' score of -0.19 indicating that Open Orphan is being referred to more favorably in the news media.

Company Overall Sentiment
Allergy Therapeutics Neutral
Open Orphan Neutral

Summary

Allergy Therapeutics beats Open Orphan on 6 of the 9 factors compared between the two stocks.

Get Allergy Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGY vs. The Competition

MetricAllergy TherapeuticsPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£90.87M£13.76B£7.83B£2.84B
Dividend Yield8.33%2.58%2.47%5.11%
P/E Ratio-1.4829.0734.3423.37
Price / Sales1.597.758.005.05
Price / Cash3.6615.7421.0220.23
Price / Book14.545.194.762.51
Net Income-£52.59M£2.88B£3.52B£5.88B
7 Day Performance14.80%-3.87%-5.34%-0.01%
1 Month Performance-68.11%-3.96%-3.61%-2.15%
1 Year Performance-82.92%-7.13%0.01%7.21%

Allergy Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGY
Allergy Therapeutics
N/AGBX 1.44
-3.7%
N/A-82.3%£90.87M£57.29MN/A612
BXP
Beximco Pharmaceuticals
N/AGBX 60.56
-3.1%
N/A+52.7%£270.17M£53.93B0.035,500
ANCR
Animalcare Group
N/AGBX 335
flat
N/AN/A£231.30M£89.11M45.89220
BVXP
Bioventix
N/AGBX 1,895.55
-1.5%
N/A-11.1%£99.04M£12.97M13.2012
VLG
Venture Life Group
N/AGBX 68.26
-0.3%
N/A+15.0%£81.14M£35.17M15.62165

Related Companies and Tools


This page (LON:AGY) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners